patent applications.

It seems that the Examiner acknowledges that the catalogues disclose a great many non-natural or unusual AAs, and considers that disclosure "essential" to practicing the invention without undue experimentation.

In our opinion, the catalogue enumerations are not essential. Chemists are well aware of what amino acids are, and how they are usually made. A specification is not supposed to be a "blueprint".

Even if they are "essential", and the reference at pp. 18-19 is properly characterized as an "improper" incorporation by reference, the proper procedure is not to reject for lack of enablement. Rather, it is to object to the specification as described in MPEP § 608.01(p)(I)(A)(2). Such an obligation may then be overcome by amending the specification to expressly recite the improperly incorporated text.

Accordingly, applicants have amended the specification to insert at page 19, line 3, a table (Reference Table A) of amino acids extracted from the three cited catalogues. The table sets forth the catalogue of origin (col. 3), the catalogue number (col. 1), and the name of the amino acid (col. 2). Claim 76 has been amended to refer to this Reference Table A. The only reference to "non-natural or unusual amino acids" in claim 18 is in clause I, however, those positions are already limited by lines 6-14 of the claim.

You will note that the selected amino acids are divided in four groups: aliphatic (Al), aromatic (Ar), basic (Ba) and acid/amide (Acm). In these four groups you will find non-natural or unusual amino acids from the catalogues which can be used as substituent(s) at relevant residues in the sequence AYMTMKIRN which can be symbolized by AlArAlAlAlBaAlBaAcm.

Thus, if identification of the contemplated non-natural or unusual AAs is "essential", the specification provides it, and

the amendment does not add new matter as the specification originally directed the reader to the three catalogues in question.

Pursuant to MPEP §608.01(p)(I)(A)(2), we hereby declare that the amendatory material consists of material previously incorporated by reference through the citation of the three catalogues in question.

2. Scope of Enablement/Peptides up to 30 AAs long (OA §4b)

The Examiner has conceded enablement for peptides of 6-20 amino acids (claim 18). Claim 22 has now been so amended, and claim 23 cancelled as inconsistent with base claim 18. Hence, this rejection is now moot.

3. Scope of Enablement/Method of Preventing or Treating (OA §4c)

The Examiner concedes that the specification is enabling for treatment of IL-10-mediated diseases other than pancreatitis, but maintains the rejection of claims 49-52, 61 and 62 insofar as they recite "prevention".

Claim 49 has been amended to avoid reference to "prevention". Claim 50 never did recite "prevention" and hence should not have been rejected. Claims 51, 52, 61 and 62 are dependent directly or indirectly on 49, and hence are "cleared" by 49's amendment.

Nonetheless, coverage of "prevention" is still sought (see Supplemental Amendment).

4. Description/New Matter Rejection to Methionine-S-Oxide and L-Dab (OA §5a)

Claim 18 was amended to recite that X_4 and/or X_5 could be "methionine-S-oxide" or that X_8 could be "L-Dab". The Examiner

rejects these additions for lack of description.

These AAs were cited in the catalogues. Hence, if that citation qualifies as an incorporation by reference --for which see pp. 10-11 of the last response-- there is not a "new matter" problem. Rather, the recitation of the subject matter in the claims renders it more likely to be "essential material", warranting an "improper incorporation by reference" objection to the specification. Reference Table A, compiled from the cited catalogues, expressly lists both methionine-S-oxide. (Novabiochem catalogue no. 04-11-0061) and L-Dab (2,4-diaminobutyric acid) (Bachem catalogue F3050).

Nonetheless, new claim 82 (of the supplemental amendment) excludes both methionine-S-oxide and L-Dab.

5. Miscellaneous

Claim 22 has been amended to resolve the inconsistency between reciting that it comprised SEQ ID NO:19 and reciting that one or more of the Thr, Lys and Arg of SEQ ID NO:19 were replaced. Claim 76 has been amended to resolve inconsistent definitions of X_A, X_B, X_C, X_4, X_5 and X_6. The definitions kept are consistent with the description of claim 76 on page 15 of the July 11, 2001 amendment.

USSN - 09/101,825

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: _____
Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
F:\,P\Plou\GronhojLarsen2\ptoamendafterfinal.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification

On page 18, line 3, please insert the enclosed "Reference Table A".

In the claims:

Claim 23 has been cancelled.

Claims 22, 49 and 76 have been amended as follows:

22 (amended). A polypeptide amounting [up to about 30] to six to twenty amino acids which comprises the following sequence

Thr-X_4-Lys-X_5-Arg-X_6 (SEQ ID NO:19),

wherein

X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu and Val; and

X_6 is selected from the group consisting of Asn, Asp, Gln and Glu,

or which comprises a sequence which differs from SEQ ID NO:19 solely in that [wherein] at least one of Thr, Lys, and Arg in SEQ ID NO:19 is independently substituted with a non-natural or unusual amino acid selected from the group consisting of the amino acids of Reference Table A,

said polypeptide having at least one of the properties defined in claim 18.

49 (amended). A method of [preventing or] treating a disease which is [preventable or] treatable by a substance which has at least one of the following properties,

a) induces inhibition of spontaneous IL-8 production by human monocytes,

b) induces inhibition of IL-1β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),

c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,

d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,

e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,

f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,

g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,

h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN-γ,

i) induces the production of IL-4 by cultured normal human CD4+ T cells,

j) reduces the TNFα production in human mixed leukocyte reaction, or

k) downregulates TNFα and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits

which comprises administering to a subject in need thereof a pharmaceutically effective amount of a pharmaceutical composition according to claim 41.

76 (amended). A non-naturally occurring polypeptide, or a polypeptide in at least partially purified form, which is six to 20 amino acids in length, and which comprises the following sequence

$$X_A-X_4-X_B-X_5-X_C-X_6$$

[wherein X_4 and X_5 are independently selected from the group consisting of Met, Ile, Leu, Val, norvaline, norleucine, methionine-S-oxide, N-methylvaline, N-methyl isoleucine, allo-leucine, and their D-isomers;

X_6 is selected from the group consisting of Asn, Asp, Gln, Glu, and their D-isomers,]

X_A is L-Thr or a non-natural or unusual amino acid,

X_B is L-Lys or a non-natural or unusual amino acid,

X_C is L-Arg or a non-natural or unusual amino acid,
X_4 and X_5 are independently selected from the group consisting of L-Met, L-Ile, L-Leu, L-Val and a non-natural or unusual amino acid,
X_6 is L-Asn, L-Asp, L-Gln, L-Glu, or a non-naturally or unusual amino acid,
no more than one of X_A, X_B, X_C, X_4, X_5 and X_6 is a non-natural or unusual amino acid other than the D-isomer of an L-amino acid recited as possible at that position,
wherein at least one of the following conditions (I)-(V) is true:

I) at least one of X_A, X_B, X_C, X_4, X_5 or X_6 is a non-natural or unusual amino acid,

II) the polypeptide is cyclized,

III) the polypeptide is stabilized,

IV) the aminoterminal amino acid residue is acylated, or

V) the carboxyterminal amino acid residue is amidated,

where, if the polypeptide is not cyclized, said sequence corresponds essentially to the C-terminal of said polypeptide, said polypeptide having at least one of the following properties:

a) induces inhibition of spontaneous IL-8 production by human monocytes,

b) induces inhibition of IL-1β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),

c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,

d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,

e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,

f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,

g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,

h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN-γ,

i) induces the production of IL-4 by cultured normal human CD4+ T cells,

j) reduces TNFα production in human mixed leukocyte reaction, or

k) downregulates TNFα and IL-8 production in a rabbit model of bile acid induced acute pancreatitis and reduces neutrophil infiltration in the lungs of the treated rabbits, and wherein any non-natural or unusual amino acid referred to above is an amino acid set forth in reference table A.

Reference Table A

	aliphatic	
04-10-0002	H-D-Ala-OH	Novabiochem
04-10-0004	H-ßAla-OH	Novabiochem
04-11-0050	C-All-L-Ala	Novabiochem
04-12-9001	H-MeAla-OH	Novabiochem
04-13-9005	H-D-MeAla-OH	Novabiochem
04-12-8000	Ac-Ala-OH	Novabiochem
04-13-8000	Ac-D-Ala-OH	Novabiochem
04-12-8001	Ac-ßAla-OH	Novabiochem
04-12-5039	Benzoyl-Ala-OH	Novabiochem
04-13-5003	Benzoyl-D-Ala-OH	Novabiochem
04-12-0510	Z-Ala-OH	Novabiochem
04-13-0500	Z-D-Ala-OH	Novabiochem
04-12-0532	Z-ßAla-OH	Novabiochem
04-13-9000	Z-D-MeAla-OH	Novabiochem
04-12-9003	Z-MeAla-OH	Novabiochem
05-22-2506	For-Ala-OH	Novabiochem
04-12-5225	p-Nitrobenzoyl-ßAla-OH	Novabiochem
04-11-0021	H-Abu-OH	Novabiochem
04-11-0046	H-γ-Abu-OH	Novabiochem
04-12-0533	Z-Abu-OH	Novabiochem
04-12-0629	Z-γ-Abu-OH	Novabiochem
04-11-0044	H-εAhx-OH	Novabiochem
04-12-0534	Z-εAhx-OH	Novabiochem
04-11-0047	H-Aib-OH	Novabiochem
04-11-0016	L-ß-t-Butylglycine	Novabiochem
04-11-0017	D-ß-t-Butylglycine	Novabiochem
04-11-0060	H-L-Cit-OH	Novabiochem
04-11-0035	H-D-Cha-OH	Novabiochem
04-11-0049	C-All-L-Gly	Novabiochem
04-12-8006	Ac-Gly-OH	Novabiochem
04-12-0509	Z-Gly-OH	Novabiochem
04-15-0002	Cap-Gly-OH	Novabiochem
04-15-0003	Lau-Gly-OH	Novabiochem
04-15-0001	Myr-Gly-OH	Novabiochem
04-15-0004	Pal-Gly-OH	Novabiochem
04-12-5233	N-Phenyl-Gly-OH	Novabiochem
04-15-0005	Ste-Gly-OH	Novabiochem
04-12-5237	Trt-Gly-OH	Novabiochem
04-10-0018	H-His-OH	Novabiochem
04-10-0059	H-D-His-OH	Novabiochem
04-10-0020	H-Hyp-OH	Novabiochem
04-12-9004	H-Melle-OH	Novabiochem
04-12-8010	Ac-Ile-OH	Novabiochem
04-12-0522	Z-Ile-OH (oil)	Novabiochem

05-22-2507	For-Ile-OH	Novabiochem
04-12-9000	Z-Melle-OH	Novabiochem
04-10-0056	H-D-Leu-OH	Novabiochem
04-12-9006	H-MeLeu-OH	Novabiochem
04-11-0067	H-Leu(γMe)-OH	Novabiochem
04-12-8012	Ac-Leu-OH	Novabiochem
04-13-8002	Ac-D-Leu-OH	Novabiochem
04-12-0501	Z-Leu-OH (oil)	Novabiochem
04-13-0512	Z-D-Leu-OH (oil)	Novabiochem
04-12-9008	Z-MeLeu-OH	Novabiochem
04-10-0028	H-D-Met-OH	Novabiochem
04-11-0061	H-Met(O)-OH	Novabiochem
04-11-0019	H-Nle-OH	Novabiochem
04-11-0041	H-D-Nle-OH	Novabiochem
04-11-0020	H-Nva-OH	Novabiochem
04-11-0042	H-D-Nva-OH	Novabiochem
04-11-0031	H-Pen-OH	Novabiochem
04-11-0032	H-D-Pen-OH	Novabiochem
04-10-0036	H-Pro-OH	Novabiochem
04-10-0037	H-D-Pro-OH	Novabiochem
04-11-0008	Thioproline	Novabiochem
04-11-0062	H-Sar-OH	Novabiochem
04-12-0581	Z-Sar-OH	Novabiochem
04-11-0015	Statine	Novabiochem
04-11-0059	ACHPA	Novabiochem
04-11-0058	AHPPA	Novabiochem
04-12-5262	H-Thr-(Bzl)-OH	Novabiochem
04-12-5003	H-Thr-(tBu)-OH	Novabiochem
04-12-0589	Z-Thr(Bzl)-OH	Novabiochem
04-12-0502	Z-Thr(tBu)-OH.DCHA	Novabiochem
04-10-0049	H-D-Val-OH	Novabiochem
04-11-0051	H-D-Val(ßOH)-OH	Novabiochem
04-12-9017	H-MeVal-OH	Novabiochem
04-13-9009	H-D-MeVal-OH.HCl	Novabiochem
04-12-8029	Ac-Val-OH	Novabiochem
04-13-8011	Ac-D-Val-OH	Novabiochem
04-12-0507	Z-Val-OH	Novabiochem
04-13-0523	Z-D-Val-OH	Novabiochem
04-12-9019	Z-MeVal-OH	Novabiochem
04-11-0003	L-Carnitine	Novabiochem
F-2740	L-alfa-aminosuberic acid	Bachem
F-1425	H-ß-Chlora-Ala-OH	Bachem
F-1460	H-ß-Cyana-Ala-OH	Bachem
F-2500	H-ß-Cyclohexyl-Ala-OH.HCl	Bachem

F-2505	H-ß-Cyclohexyl-D-Ala-OH.HCl	Bachem
F-1470	H-ß-(1-Cyclopentenyl)-DL-Ala-OH	Bachem
F-1465	H-ß-Cyclopentyl-DL-Ala-OH	Bachem
F-1475	L-Cycloserine	Bachem
F-1480	D-Cycloserine	Bachem
F-2985	H-4,5-Dehydro-Leu-OH	Bachem
F-1490	H-3,4-Dehydro-Pro-OH	Bachem
F-1160	H-allo-Ile-OH	Bachem
F-1165	H-D-allo-Ile-OH	Bachem
F-1175	H-allo-Thr-OH	Bachem
F-1180	H-D-allo-Thr-OH	Bachem
F-2540	H-allo-Thr(tBu)-OH	Bachem
F-1205	7-Aminoheptanoic acid	Bachem
F-1281	L-Axetidine-2-carboxylic acid	Bachem
F-2285	Azetidine-3-carboxylic acid	Bachem
F-2395	H-α-Difluoro-Me-DL-Orn-OH	Bachem
F-2530	H-ß-Fluora-DL-Ala-OH	Bachem
B-1910	Fmoc-γ-Abu-OH	Bachem
F-2780	H-Homoarg-OH	Bachem
F-1625	H-Homopro-OH	Bachem
F-1630	H-D-Homopro-OH	Bachem
F-1765	N-Me-Aib-OH	Bachem
F-1800	H-α-Me-DL-Leu-OH	Bachem
F-2895	H-Met(O_2)-OH	Bachem
F-2550	Myristoyl-Gly-OH	Bachem
F-1315	H-Neopentylgly-OH	Bachem
F-1320	H-D-Neopentylgly-OH	Bachem
F-2040	H-Propargyl-Gly-OH	Bachem
F-2900	H-D-Propargyl-Gly-OH	Bachem
C-1535	Z-dehydro-Ala-OH	Bachem
FA02901	Fmoc-D-2-aminobutyric acid	Neosystem
AA03001	H-4-aminobutyric acid	Neosystem
AA03201	H-8-aminocaprylic acid	Neosystem
FA03301	Fmoc-1-amino-1-cyclohexane carboxylic acid	Neosystem
FA12101	Fmoc-(3S,4S,5S)-4-amino-3-hydroxy-5-methyl-heptanoic acid	Neosystem
BA03804	Boc-(3S,4S)-4-amino-3-hydroxy-5-(4-benzyloxyphenyl)-pentanoic acid	Neosystem
FA03103	Fmoc-(3S,4S)-4-amino-3-hydroxy-6-methylthio-hexanoic acid	Neosystem
AA03601	H-2-aminoisobutyric acid	Neosystem
AA05201	H-D-2-aminovaleric acid	Neosystem
AA05202	H-L-2-aminovaleric acid	Neosystem
FA03801	Fmoc-5-aminovaleric acid	Neosystem
FA04102	Fmoc-L-α-t-butylglycine	Neosystem

40

FA09401	Fmoc-(4-carboxymethyl)-piperidine	Neosystem
FA11701	(R,S)-Fmoc-2-carboxymorpholine	Neosystem
FA02301	Fmoc-ß-cyclohexyl-D-alanine	Neosystem
FA02302	Fmoc-ß-cyclohexyl-L-alanine	Neosystem
FA11901	Fmoc-D-homoleucine	Neosystem
FA11902	Fmoc-L-homoleucine	Neosystem
AA04802	H-L-hydroxyproline	Neosystem
FA04804	Fmoc-O-t-butyl-L-hydroxyproline	Neosystem
FA09001	Fmoc-isonipecotic acid	Neosystem
FA01220	Fmoc-L-Lys(Biotin)-OH	Neosystem
AA05101	H-D-norleucine	Neosystem
AA05102	H-L-norleucine	Neosystem
AA05201	H-D-norvaline	Neosystem
AA05202	H-L-norvaline	Neosystem
AA08602	H-L-ornithine.HCl	Neosystem
AA00811	H-sarcosine	Neosystem
FA08901	Fmoc-statine	Neosystem
FA06502	Fmoc-L-thiazolidine-4-carboxylic acid	Neosystem
FA09701	Fmoc-tranexamic acid	Neosystem
FB02301	(3S)-Fmoc-3-amino-1-carboxymethyl-caprolactame	Neosystem
FB02801	(2S,6S,9S)-Fmoc-6-amino-2-carboxymethyl-3,8-diazzabicyclo-[4,3,0]-nonane-1,4-dione	Neosystem
FB02601	Fmoc-BTD	Neosystem
FB02101	Fmoc-"Freidinger's lactame"	Neosystem
BB01502	Boc-Pro-ψ[CH_2N(2-Cl-Z)]-Gly-OH	Neosystem
aromatic		
04-11-0066	H-Nal-OH	Novabiochem
04-11-0001	H-D-Nal-OH	Novabiochem
04-10-0032	H-D-Phe-OH	Novabiochem
04-11-0054	H-Phe(pCl)-OH	Novabiochem
04-11-0048	H-D-Phe(pCl)-OH	Novabiochem
04-11-0024	H-Phe(2F)-OH	Novabiochem
04-11-0025	H-Phe(3F)-OH	Novabiochem
04-11-0026	H-Phe(pF)-OH	Novabiochem
04-12-7500	H-α-Me-Phe-OH	Novabiochem
04-12-9009	H-MePhe-OH	Novabiochem
04-13-9007	H-D-MePhe-OH. HCl	Novabiochem
04-11-0045	H-Phe(NO_2)-OH. H_2O	Novabiochem
04-12-8018	Ac-Phe-OH	Novabiochem
04-13-8005	Ac-D-Phe-OH	Novabiochem
04-12-5139	Benzoyl-Phe-OH	Novabiochem
04-13-5031	Benzoyl-D-Phe-OH	Novabiochem

04-12-0500	Z-Phe-OH	Novabiochem
04-13-0516	Z-D-Phe-OH	Novabiochem
04-12-9021	Z-MePhe-OH	Novabiochem
04-10-0034	H-Phg-OH	Novabiochem
04-10-0035	H-D-Phg-OH	Novabiochem
04-11-0029	D-(-)-Dihydrophenylglycine	Novabiochem
04-12-0575	Z-Phg-OH	Novabiochem
04-11-0062	H-Tic-OH	Novabiochem
04-11-0063	H-Tic(OH)-OH. $2H_2O$	Novabiochem
04-11-0036	H-Thi-OH	Novabiochem
04-10-0043	H-Trp-OH	Novabiochem
04-10-0044	H-D-Trp-OH	Novabiochem
04-11-0038	5-Hydroxy-L-Trp-OH	Novabiochem
04-12-5186	H-Trp(Boc)-OH	Novabiochem
04-13-5066	H-D-Trp(Boc)-OH	Novabiochem
04-10-0047	H-D-Tyr-OH	Novabiochem
04-11-0014	H-Tyr(3',5'-di-I)-OH	Novabiochem
04-12-5013	H-Tyr(Bzl)-OH	Novabiochem
04-12-5012	H-Tyr(tBu)-OH	Novabiochem
04-13-5056	H-D-Tyr(tBu)-OH	Novabiochem
F-1305	H-p-Bromo-Phs-OH	Bachem
F-2800	H-p-Bz-Phe-OH	Bachem
F-2810	H-p-Bz-D-Phe-OH	Bachem
F-1445	H-p-Chloro-Phe-OH	Bachem
F-2520	H-p-Chloro-D-Phe-OH	Bachem
F-1200	H-4-Amino-3,5-diiodo-Phe-OH	Bachem
F-1225	H-p-Amino-Phe-OH. HCl	Bachem
F-2855	H-p-Amino-D-Phe-OH. HCl	Bachem
F-2490	H-ß-(3-Benzothienyl)-Ala-OH	Bachem
F-2485	H-ß-(3-Benzothienyl)-D-Ala-OH	Bachem
F-1520	H-3,5-Dibromo-Tyr-OH	Bachem
F-2225	H-3,5-Diiodo-Tyr-OH	Bachem
F-3005	H-3,5-Diiodo-D-Tyr-OH	Bachem
F-1530	H-p-Fluoro-Phe-OH	Bachem
F-2320	H-p-Fluoro-D-Phe-OH	Bachem
F-2135	H-m-Flouro-DL-Phe-OH	Bachem
B-2360	Fmoc-p-azido-Phe-OH	Bachem
B-2220	Fmoc-p-Bz-Phe-OH	Bachem
F-1610	H-Homophe-OH	Bachem
F-1615	H-D-Homophe-OH	Bachem
F-1670	H-p-iodo-D-Phe-OH	Bachem
F-1675	H-p-iodo-DL-Phe-OH	Bachem
E-3150	H-α-Me-Phe-OH	Bachem

F-3115	H-α-Me-D-Phe-OH	Bachem
F-1810	H-α-Me-DL-Trp-OH	Bachem
F-2820	H-ß-(2-Pyridyl)-Ala-OH	Bachem
F-2790	H-ß-(2-Pyridyl)-D-Ala-OH	Bachem
FA02601	Fmoc-2-aminobenzoic acid	Neosystem
FA02801	Fmoc-4-aminobenzoic acid	Neosystem
FA12401	Fmoc-3-amino-1-carboxymethyl-pyridin-2-one	Neosystem
BA03805	Boc-(3S,4S)-4-amino-3-hydroxy-5-(3-indolyl)-pentanoic acid	Neosystem
BA03701	Boc-(3S,4S)-4-amino-3-hydroxy-5-phenyl-pentanoic acid	Neosystem
FA08801	Fmoc-2-aminoindane-2-carboxylic acid	Neosystem
FA02702	Fmoc-(3-aminomethyl)-benzoic acid	Neosystem
FA09201	Fmoc-(D,L)-2-aminotetraline-2-carboxylic acid	Neosystem
FA01406	Fmoc-4-bromo-D-phenylalanine	Neosystem
FA01407	Fmoc-4-bromo-L-phenylalanine	Neosystem
FA05602	Fmoc-4-chloro-L-phenylalanine	Neosystem
FA05701	Fmoc-3,4-dichloro-D-phenylalanine	Neosystem
FA05702	Fmoc-3,4-dichloro-L-phenylalanine	Neosystem
FA11801	(R,S)-Fmoc-1,3-dihydro-2H-isoindole carboxylic acid	Neosystem
FA05801	Fmoc-4-fluoro-D-phenylalanine	Neosystem
FA05802	Fmoc-4-fluoro-L-phenylalanine	Neosystem
FA05002	Fmoc-L-indoline-2-carboxylic acid	Neosystem
FA01221	Fmoc-L-Lys(Dabcyl)-OH	Neosystem
FA01410	Fmoc-4-methyl-D-phenylalanine	Neosystem
FA01411	Fmoc-4-methyl-L-phenylalanine	Neosystem
FA02506	Fmoc-D-1-naphthylalanine	Neosystem
FA02505	Fmoc-L-1-naphthylalanine	Neosystem
FA02503	Fmoc-D-2-naphthylalanine	Neosystem
FA02504	Fmoc-L-2-naphthylalanine	Neosystem
FA06001	Fmoc-4-nitro-D-phenylalanine	Neosystem
FA06002	Fmoc-4-nitro-L-phenylalanine	Neosystem
FA07102	Fmoc-3-nitro-L-tyrosine	Neosystem
FA09801	Racemic Fmoc-trans-3-phenylazetidine-2-carboxylic acid	Neosystem
FA08001	Fmoc-D-3-pyridylalinine	Neosystem
FA08002	Fmoc-L-3-pyridylalanine	Neosystem
FA09501	Fmoc-D-tetrahydroisoquinoline-2-carboxylic acid	Neosystem
FA09502	Fmoc-L-tetrahydroisoquinoline-2-carboxylic acid	Neosystem
AA06601	1,2,3,4-D-tetrahydroisoquinoline-3-carboxylic acid	Neosystem
AA06602	1,2,3,4-L-tetrahydroisoquinoline-3-carboxylic acid	Neosystem
FA12501	Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid	Neosystem
FA02501	Fmoc-ß-(2-thienyl)-D-alanine	Neosystem
FA02502	Fmoc-ß-(2-thienyl)-L-alanine	Neosystem
FB02201	(R,S)-Fmoc-3-amino-N-1-carboxymethyl-2-oxo-5-phenyl-1,4-benzodiazepine	Neosystem
FB02401	(R,S)-Fmoc-3-amino-1-carboxymethyl-2,3,4,5-tetrahydro-1H-	Neosystem

	[1]-benzazepine-2-one	
FB02501	Fmoc-3-(2-aminoethyl)-1-carboxymethyl-quinazoline-2,4-dione	Neosystem
FB02701	(2S,5S)-Fmoc-5-amino-1,2,4,5,6,7-hexahydro-azepino [3,2,1-hi] indole-4-one-2-carboxylic acid	Neosystem
basic		
04-11-9024	H-Arg(OH)-OH. AcOH	Novabiochem
04-11-9022	H-Arg(Me)-OH. AcOH	Novabiochem
04-11-9023	H-D-Arg(Me)-OH. AcOH	Novabiochem
04-10-0060	H-D-Lys-OH	Novabiochem
04-10-0030	H-Orn-OH. HCl	Novabiochem
04-10-0066	H-D-Orn-OH. HCl	Novabiochem
F-3050	L-α, γ-Diaminobutyric acid. 2HCl	Bachem
F-3055	D-α, γ-Diaminobutyric acid. 2HCl	Bachem
F-1505	2,6-Diaminopimelic acid (LL, DD and meso)	Bachem
F-3040	L-α, ß-Diaminopropionic acid. HCl	Bachem
F-3045	D-α, ß-Diaminopropionic acid. HCl	Bachem
FA12001	Fmoc-4-(2-aminoethyl)-1-carboxymethyl-piperazine dihydrochloride	Neosystem
FA09301	N,N-bis(N'-Fmoc-3-aminopropyl)-glycine potassium hemisulfate	Neosystem
FA11601	Fmoc-4-carboxymethyl-piperazine	Neosystem
FA00804	N-α-Fmoc-N-α'-Boc-diaminoacetic acid	Neosystem
BA03904	N-α-Boc-N-γ-Fmoc-L-diaminobutyric acid	Neosystem
FA03904	N-α-Fmoc-N-γ-Boc-L-diaminobutyric acid	Neosystem
BA04005	N-α-Boc-N-ß-Fmoc-D-diaminopropionic acid	Neosystem
BA04006	N-α-Boc-N-ß-Fmoc-L-diaminopropionic acid	Neosystem
FA04004	N-α-Fmoc-N-ß-Boc-L-diaminopropionic acid	Neosystem
BB01102	Boc-Leu-ψ(CH_2NH)-Phe-OH	Neosystem
BB01401	Boc-Phe-ψ(CH_2NH)-Phe-OH	Neosystem
BB01501	Boc-Pro-ψ(CH_2NH)-Gly-OH	Neosystem
acidic/amide		
04-11-0070	H-Asu-OH. HCl	Novabiochem
04-10-0009	H-D-Asn-OH. H_2O	Novabiochem
04-10-0011	H-D-Asp-OH	Novabiochem
04-10-0016	H-D-Glu-OH	Novabiochem
04-10-0058	H-D-Gln-OH	Novabiochem
04-12-5261	H-Lys(Ac)-OH	Novabiochem
04-12-5117	H-Lys(Boc)-OH	Novabiochem
04-12-5022	H-Lys(Z)-OH	Novabiochem
04-13-5052	H-D-Lys(Z)-OH	Novabiochem

04-12-5245	H-Lys(Tfa)-OH	Novabiochem
04-12-5283	H-Orn(Boc)-OH	Novabiochem
04-13-5021	H-D-Orn(Boc)-OH	Novabiochem
04-12-5134	H-Orn(Z)-OH	Novabiochem
F-2560	L-α-Aminoadipic acid	Bachem
F-2575	D-α-Aminoadipic acid	Bachem
F-3150	L-α-Aminoadipic acid - δ-t-butylester	Bachem .
F-2030	H-Ser(PO_3H_2)-OH	Bachem
F-2035	H-D-Ser(PO_3H_2)-OH	Bachem
FA04008	N-α-Fmoc-N-ß-Z-L-diaminopropionic acid	Neosystem
ZA04006	N-α-Z-N-ß-Fmoc-L-diaminopropionic acid	Neosystem
FB01501	Fmoc-(S,S)-[Pro-Leu]-spirolactame	Neosystem

- Novabiochem, 1994/1995 Catalogue (Calbiocem-Novabiocem AG, Weidenmattweg 4, CH-4448 Läufelfinden/Switzerland, Pages 65-125
- Bachem Feinchemikalien AG 1995 Katalog (Bachem Feinchemikalien AG, Hauptstraße 144, CH-4416 Bubendoft/Switzerland), Pages 753-831
- Neosystem Laboratorie Catalogue 1997/98 (Neosystem Laboratoire, 7 rue de Boulogne, 67100 Strasbourg, France) Pages 131-176